Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P A Marks

Showing results (181-190 of 189) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 189 results.
The Journal of Clinical Investigation|November 7, 2001
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemiaL Z He, T Tolentino, P Grayson, et al.
Blood|November 15, 1992
Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agentM Andreeff, R Stone, J Michaeli, et al.
Medical and Pediatric Oncology|December 7, 2000
Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitroD C Coffey, M C Kutko, R D Glick, et al.
In Vitro|January 1, 1978
Regulation of differentiation in normal and transformed erythroid cellsR A Rifkind, P A Marks, A Bank, et al.
The Journal of Biological Chemistry|May 13, 1999
Photoaffinity labeling and mass spectrometry identify ribosomal protein S3 as a potential target for hybrid polar cytodifferentiation agentsY Webb, X Zhou, L Ngo, et al.
Cancer Research|December 15, 1988
Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervalsC W Young, M P Fanucchi, T Declan Walsh, et al.
Cancer Research|April 28, 2001
The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acidD C Coffey, M C Kutko, R D Glick, et al.
Cancer Research|October 4, 2000
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivoL M Butler, D B Agus, H I Scher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2001
Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylaseL M Butler, Y Webb, D B Agus, et al.
Pageof 19

Showing results (181-190 of 189) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 189 results.
The Journal of Clinical Investigation|November 7, 2001
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemiaL Z He, T Tolentino, P Grayson, et al.
Blood|November 15, 1992
Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agentM Andreeff, R Stone, J Michaeli, et al.
Medical and Pediatric Oncology|December 7, 2000
Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitroD C Coffey, M C Kutko, R D Glick, et al.
In Vitro|January 1, 1978
Regulation of differentiation in normal and transformed erythroid cellsR A Rifkind, P A Marks, A Bank, et al.
The Journal of Biological Chemistry|May 13, 1999
Photoaffinity labeling and mass spectrometry identify ribosomal protein S3 as a potential target for hybrid polar cytodifferentiation agentsY Webb, X Zhou, L Ngo, et al.
Cancer Research|December 15, 1988
Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervalsC W Young, M P Fanucchi, T Declan Walsh, et al.
Cancer Research|April 28, 2001
The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acidD C Coffey, M C Kutko, R D Glick, et al.
Cancer Research|October 4, 2000
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivoL M Butler, D B Agus, H I Scher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2001
Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylaseL M Butler, Y Webb, D B Agus, et al.
Pageof 19